Sixty-seven oncology physician group practices in 37 states will participate in the Enhanced Oncology Model, a voluntary five-year payment model that will begin July 1 for beneficiaries who receive systemic chemotherapy, the Centers for Medicare & Medicaid Services announced yesterday. The Center for Medicare and Medicaid Innovation model supports the administration’s moonshot goal to reduce cancer death rates by 50% over the next 25 years. Participating practices must provide 24/7 access to care, patient navigation and care planning; use certified electronic health record technology, evidence-based guidelines, electronic patient reported outcomes and data to improve quality; and must also screen for health-related social needs. The model will qualify as an alternative payment model under the Quality Payment Program’s Merit-based Incentive Payment System beginning in July. It offers two levels of downside risk, with the higher risk arrangement excluded from MIPS reporting requirements and payment adjustments as an Advanced APM. For more, see the model’s updated fact sheet.

Related News Articles

Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
Ashley Thompson, AHA senior vice president of public policy analysis and development, participated in a panel discussion during Modern Healthcare's Leadership…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…